Lilly reports Foundayo obesity risk analysis
Eli Lilly (NYSE:LLY) reported post-hoc analyses from the Phase 3 ATTAIN-1 trial showing Foundayo was associated with lower modeled 10-year risks of type 2 diabetes and cardiovascular disease in adults with obesity or overweight.



-640x360.webp&w=3840&q=75)






